Study details
Enrolling now
Study of Novel Therapeutics for Acute Remedy of Colitis
Brigham and Women's Hospital
NCT IDNCT06420492ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 1.7 years
Ages
18–75
Locations
1 site in MA
What this study is about
Researchers are testing a treatment called BRS201 to see if it helps people with acute ulcerative colitis. The trial will last 609 days and involve taking the medication twice daily, tracking its use, and undergoing some tests. Participants will attend trial visits at a site.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BRS201
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Gastroenterology